Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
Stocks · News reference
Tempus AI Extends Recursion Data Deal Through 2029, Replacing Potential $84M Fees With $42M In Committed Payments, In Addition To Licensing Recursion’s RNA Foundation Model "TxFM" Under A Separate License Agreement
Tempus AI, Inc. (NASDAQ:TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). Additionally, the two companies have entered into a new agreement under which
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
'HHS launches project to speed up clinical trials' - Axios
Squeeze Watch: 10 Stocks With Over 33% Short Interest
Ten stocks have over 34% of their float short, with ONDS and BROS on the list led by VG.
S&P 500, Nasdaq Hit Records, Power Stocks Rally on Google's Nuclear Deal: Stock Market Today
S&P 500 and Nasdaq 100 hit records as the 10-year yield retreats from a 24-year high; Constellation Energy jumps on a Google nuclear deal.
Cathie Wood Claps Back After Being Confronted as ARKK Fell Nearly 15% While QQQ Soared 112% in Five Years — Calls It an ‘Incorrect Comparison’
Cathie Wood defends ARKK's 15% drop vs QQQ's 112% 5-year gain, calling it an 'incorrect comparison' and blaming 'endpoint sensitivity.'
Stock Market Today: S&P 500 Slips as Micron Fails to Impress, 10-Year Yields Ease to 5.25%
Micron slides despite a record quarter as the 10-year yield nears 5.3% and oil tops $92, while Accenture, Coherent and Vicor surge on earnings and AI optics.